AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by AYTU BIOPHARMA, INC. on June 29, 2022, reporting events occurring on June 24, 2022. The Company is a Delaware corporation with its principal executive offices in Englewood, Colorado, and its common stock trades on The NASDAQ Stock Market LLC under the symbol "AYTU".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of a new director to the Board of Directors.
- Appointment: Vivian Liu was appointed to the Board of Directors, effective July 1, 2022.
- Term: Ms. Liu's term will expire at the Company's 2023 Annual Meeting of Stockholders.
- Committee Assignment: Ms. Liu was appointed to the Nominating and Corporate Governance Committee.
Compensatory Arrangements and Outlook
Ms. Liu will participate in the Company's non-employee director compensation program. Upon initial appointment, she received a grant of 6,500 restricted shares of the Company's common stock. The equity grant vests one-third on July 1, 2023, with the remaining shares vesting ratably over the following eight quarters. The filing does not contain management commentary on business outlook, risks, or contingencies beyond the standard disclosure of the appointment.
Investor Verification Checklist
- Verify the effective date of Vivian Liu's board appointment (July 1, 2022).
- Review the vesting schedule for the 6,500 restricted shares granted to Ms. Liu.
- Confirm Ms. Liu's assignment to the Nominating and Corporate Governance Committee.
- Consult the Company's 2022 Proxy Statement (filed April 7, 2022) for the full details of the non-employee director compensation program.